Browsing by author "Evans, Rachel"

Now showing items 1-4 of 4

    • Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma. 

      Evans, RJ; Perkins, DW; Selfe, J; Kelsey, A; Birch, GP; et al. (AMER ASSOC CANCER RESEARCH, 2023-02-01)
      Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, ...

    • Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis. 

      Jungwirth, U; van Weverwijk, A; Evans, RJ; Jenkins, L; Vicente, D; et al. (NATURE PORTFOLIO, 2021-06-10)
      Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ...

    • RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. 

      Irshad, S; Flores-Borja, F; Lawler, K; Monypenny, J; Evans, R; et al. (AMER ASSOC CANCER RESEARCH, 2017-03-01)
      Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the human breast tumor ...

    • Targeting Endo180 with an antibody-drug conjugate for cancer treatment 

      Isacke C; Evans, R; Isacke, C (Institute of Cancer Research (University Of London), 2024-03-22)
      Antibody-drug conjugates (ADCs) are formed of an antibody attached to a cytotoxic drug via a linker which is cleaved upon internalisation of the ADC into the cell. This allows very toxic drugs to be directed to specific ...